Nature

Rapid functional cardiac imaging after gadolinium injection: Evaluation of a highly accelerated sequence with sparse data sampling and iterative reconstruction

To generate a patient-friendly, time-efficient cardiac MRI examination protocol, a highly accelerated real-time CINE MR sequence (SSIR) was acquired in the idle time in between contrast injection and ...
Medindia

Information Update - New safety information on injectable gadolinium-based contrast agents used in MRI scans

OTTAWA, Jan. 6, 2017 /CNW/ - Health Canada has conducted a safety review of gadolinium-based contrast agents (GBCAs) due to growing scientific evidence that gadolinium may accumulate in the brain ...
GlobalData on MSN

FDA approves Bayer’s Ambelvist contrast agent

The approval is based on global Phase III QUANTI studies evaluating Ambelvist's efficacy and safety in adults and children.
KXAN

Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High-Relaxivity Gadolinium-Based Contrast Agent which will be commercialized as VUEWAY ...

VUEWAY injection is highly stable and shows the highest relaxivity among gadolinium-based contrast agents available for clinical use i VUEWAY injection is approved for use in adult and pediatric ...
Monthly Prescribing Reference

Gadopiclenol, a New Macrocyclic Gadolinium-Based Contrast Agent, Gets FDA Approval

Gadopiclenol carries a Boxed Warning associated with an increased risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. The approval of gadopiclenol was based on ...
Business Wire

Fresenius Kabi Expands Contrast Agent Portfolio with Launch of Gadoterate Meglumine Injection, USP

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent ...
Neurology Advisor

FDA Approves Lower-Dose Gadolinium Contrast Agent Ambelvist

The FDA has approved Bayer’s Ambelvist (gadoquatrane), the lowest-dose macrocyclic GBCA for adult and pediatric contrast-enhanced CNS and body MRI exams.
Morningstar

Bracco Receives Health Canada Approval for VUEWAY® injection (gadopiclenol), Advancing Lower-Dose MRI Contrast Imaging

Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance to use the lowest effective dose MONTREAL, April 17, 2026 ...
Yahoo Finance

FDA Approves VUEWAY® (gadopiclenol) Solution for Injection, Intravenous Use, for Use in Neonates and Infants

"In the delivery of medical care, and particularly for our care of neonates and young children, we must consider potential long-term implications of our decisions today," said Teresa Chapman, MD, MA, ...
Business Insider

Guerbet concurs with the PRAC Recommendations on Gadolinium-based Contrast Agents and announces changes to the US labeling for its linear agent Optimark® (gadoversetamide ...

PRINCETON, N.J., March 31, 2017 /PRNewswire/ -- Guerbet LLC., subsidiary of Guerbet Group (FR0000032526 GBT), the global specialist in contrast products and solutions for medical imaging, takes note ...
Business Wire

GE Healthcare Announces U.S. FDA Approval of Macrocyclic MRI Contrast Agent Clariscan™ (gadoterate meglumine) Injection for Intravenous Use

CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...